Targeted hydrogel for prevention of neuromuscular contractures
This technology is a drug-releasing hydrogel designed to prevent muscle contractures and associated deformities in children with neuromuscular diseases by targeting the underlying molecular cause.
Unmet Need: Treatments to prevent neuromuscular contracture formation
Current treatments for neuromuscular contractures, such as Botox or phenol injections, primarily target muscle spasticity but do not prevent contractures from forming. As a result, children with neuromuscular diseases remain at risk for developing progressive joint stiffness and musculoskeletal deformities that can significantly impair mobility and quality of life. There is a critical need for treatments that address the underlying cause of contracture formation rather than simply managing symptoms.
The Technology: Targeted hydrogel delivery to prevent neuromuscular contractures
This technology is a biocompatible, drug-releasing hydrogel to prevent neuromuscular contracture formation by targeting abnormal BMP2/SMAD4 signaling, a molecular pathway identified as contributing to contracture development. The hydrogel is composed of PLGA-PEG-PLGA polymers and is designed to deliver therapeutic agents directly to affected tissues, addressing an underlying cause of contractures rather than simply managing symptoms. This approach has potential applications in preventing musculoskeletal deformities associated with neuromuscular diseases, including cerebral palsy and spinal muscular atrophy.
This technology has been evaluated in a murine model of neuromuscular contractures, with initial results demonstrating safety and efficacy in preventing contracture formation.
Applications:
Prevention of contractures in children with cerebral palsy, spinal muscular atrophy, and other neuromuscular diseases
Prevention of neuromuscular deformities, including scoliosis, and foot, arm, and leg contractures.
Targeted drug delivery for preventing contracture formation
Research into BMP2/SMAD4 signaling and molecular pathways involved in contracture development
Prevention of mobility limitations associated with neuromuscular disorders
Advantages:
Targets the underlying cause of contractures by addressing molecular signaling
Provides a biocompatible delivery system with established biomedical applications
Offers broad therapeutic potential
Demonstrates safety and efficacy in preclinical animal model
Promotes localized drug delivery
Has the potential to reduce invasive and expensive interventions
Lead Inventor:
Related Publications:
Tech Ventures Reference:
IR CU26103
Licensing Contact: Jerry Kokoshka